Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
NHS_1
Study information
Scientific title
Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma
Acronym
Study hypothesis
Not provided at time of registration
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Carcinoma of the pancreas
Intervention
1. Group A: Flutamide 250 mg three times daily
2. Group B: Placebo
Intervention type
Drug
Phase
Phase III
Drug names
Drogenil (flutamide)
Primary outcome measure
Not provided at time of registration
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/01/1995
Overall trial end date
31/01/1997
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Not provided at time of registration
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
Not provided at time of registration
Participant exclusion criteria
Not provided at time of registration
Recruitment start date
01/01/1995
Recruitment end date
31/01/1997
Locations
Countries of recruitment
United Kingdom
Trial participating centre
MRC Clinical Trials Unit
London
NW1 2DA
United Kingdom
Funders
Funder type
Industry
Funder name
Schering-Plough Ltd (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
1998 presumed results in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28589/ (added 30/10/2019)